Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842188 | 0.94 | LTA4H (0.51) | LTA4HACHECHEK2TBK1MEN1 | |
| Trifluoroacetic Acid SCHEMBL4842116 | 0.89 | CHEK2 (0.53) | ACHECHEK2TBK1 | |
| Trifluoroacetic Acid SCHEMBL4845497 | 0.88 | ABCB1 (0.44) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4842301 | 0.87 | DRD2 (0.54) | ACHECHEK2TBK1DRD3DRD2 | |
| SCHEMBL6218461 | 0.87 | TBK1 (0.44) | LTA4HACHECHEK2TBK1MEN1 | |
| Trifluoroacetic Acid SCHEMBL4841456 | 0.87 | CHEK2 (0.45) | ACHECHEK2TBK1DRD3DRD2 | |
| Trifluoroacetic Acid SCHEMBL4843197 | 0.87 | TBK1 (0.51) | ACHECHEK2TBK1ALDH1A1DRD3 | |
| Trifluoroacetic Acid SCHEMBL4841636 | 0.86 | ACHE (0.53) | ACHECHEK2TBK1 | |
| Trifluoroacetic Acid SCHEMBL4840800 | 0.86 | CHEK2 (0.45) | ACHECHEK2TBK1DRD3 | |
| Trifluoroacetic Acid SCHEMBL4846269 | 0.85 | CHEK2 (0.44) | ACHECHEK2TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | LTA4H 2694/4885ACHE 1390/4885CHEK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.